Short answer
CASTLE BIOSCIENCES INC (CSTL) filed its Q3 2025 10-Q quarterly report on Nov 3, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $83M (down 3.2% year over year) with net income of −$501,000.
Q3 2025 key financials · XBRL
- Revenue
- $83M
- −3.2% YoY · −3.6% QoQ
- Net income
- −$501,000
- −122.1% YoY · −111.1% QoQ
- Operating margin
- -8.2%
- EPS (diluted)
- −$0.02
- −125.0% YoY · −112.5% QoQ
Source: XBRL data from the CASTLE BIOSCIENCES INC (CSTL) Q3 2025 10-Q on SEC EDGAR. USD.
CASTLE BIOSCIENCES INC Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Test reports 26,841, up 3.2% YoY
- TissueCypher strongest growth, 10,609 reports, up 74.7% YoY
- IDgenetix weakest trend, 0 reports after discontinuation in May 2025
- Near-term headwinds: Medicare noncoverage of DecisionDx-SCC and macroeconomic uncertainty
Risk Factors
- Newly triggered coverage risk: Novitas LCD effective April 24, 2025 classifies DecisionDx-SCC as noncovered
- Regulatory risk: FDA rescinded LDT final rule September 19, 2025 after Texas court vacatur, leaving future oversight uncertain
- Reimbursement risk: DecisionDx-SCC revenue expected to decline materially from its significant 2024 contribution
- Financial risk: Nine-month 2025 net loss $21.8 million and accumulated deficit $222.0 million
- Operational risk: TissueCypher previously required a temporary order pause to address a significant testing backlog
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CASTLE BIOSCIENCES INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.